FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
about
Sunitinib: the antiangiogenic effects and beyondDouble-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Integration of drug, protein, and gene delivery systems with regenerative medicine.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learnedThe use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.A woman with metastatic pancreatic neuroendocrine tumor.Current understanding of the molecular biology of pancreatic neuroendocrine tumors.Pancreatic NETs: where do we stand now?Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Large scale integration of drug-target information reveals poly-pharmacological drug action mechanisms in tumor cell line growth inhibition assays.Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growthThe pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer.Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer.Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumourSynthesis, Crystal Structure, and Biological Activity ofcis/transAmide Rotomers of (Z)-N′-(2-Oxoindolin-3-ylidene)formohydrazide
P2860
Q28066499-C2D02DB6-0EAD-4DED-860C-F743686D878CQ33411581-B4EDD040-004F-4019-95F7-6634B5613A16Q35241569-392331C3-FFF1-4CF3-8859-3375FC017D87Q35434188-6843F926-BE2C-4F14-8AA3-E917619FA9A7Q36871673-B1E9C1BA-CBCA-492B-AD8E-D2C383F59D7CQ37117596-5E1A2BD4-B5E6-4619-BE44-09A05D1405DBQ37584857-AD2BDBED-F52B-49ED-9DE8-C362F5D9D929Q38120515-13E76EAB-A60D-4E49-9CCF-ED6FE3FC242CQ38181004-E78F302B-24D8-43E1-9B76-15E9EB7CDAD8Q38635940-EBCA58AB-7A2B-468A-8092-5C02CCC56BFBQ38679359-4F8A5A3A-045E-488C-B394-77E66D93A389Q38880510-7D4B29EA-8C16-479E-8254-EE008409EF00Q38915003-CA1EB035-13E6-43BD-BAF3-0658AC14E027Q39413595-1BBFDF59-07E5-413E-930D-9A8A019055B9Q39635470-A06113B1-8F4D-442F-8A33-7CD9C54BD527Q48159588-4D4FEBC1-0E81-4F09-A440-1EAF819144ACQ51097491-69421C19-FDAE-46F9-85EC-23B23DB5EF03Q54299389-19FD782B-267A-4A67-A534-ABBD09CB3F61Q58753938-9B23CA4A-2756-4A14-9C4C-B7AA7B83E1C8Q59054840-02E90C19-3D87-4E22-A163-116111251113
P2860
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@ast
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@en
type
label
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@ast
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@en
prefLabel
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@ast
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@en
P2093
P2860
P1433
P1476
FDA approval summary: sunitini ...... creatic neuroendocrine tumors.
@en
P2093
Anthony Murgo
Gideon M Blumenthal
Jenny J Zhang
Patricia Cortazar
Rajeshwari Sridhara
Richard Pazdur
Robert Justice
Shenghui Tang
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0044
P577
2012-07-26T00:00:00Z